Search
Search
Search results 20
Visit AmoyDx at the 19th World Conference on Lung Cancer (WCLC) 2018 in Canada
Amoy Diagnostics will be exhibiting at 19th World Conference on Lung Cancer 2018 of IASLC in Toronto, Canada. Welcome to visit us at booth 206.
News & Events
Meet AmoyDx at ELCC 2018 in Switzerland for NSCLC Molecular Testing
Amoy Diagnostics will be exhibiting at the ELCC 2018 in Geneva, Switzerland. Welcome to visit us.  The exhibition details are below.
News & Events
China NMPA grants approval to AmoyDx Super-ARMS EGFR mutation test kit
(January 22, 2018, Xiamen China)  Amoy Diagnostics Co., Ltd. (AmoyDx, SZ:300685)  announced that NMPA(National Medical Products Administration)approved AmoyDx Super-ARMS® EGFR mutation test kit
News & Events
AmoyDx Distributors Annual Meeting (APAC-MEAF) 2017
AmoyDx Distributors Annual Meeting (APAC-MEAF) 2017 was held in Xiamen, China on December 4. Distributors from different countries gathered to get the recent update on precision oncology
News & Events
AmoyDx Distributors Annual Meeting (Europe) 2017
AmoyDx Distributors Annual Meeting (Europe) 2017 was held in Dusseldorf, Germany on November 15. Distributors from different European countries gathered to get the recent update on precision oncology
News & Events
Visit AmoyDx at MEDICA 2017, Germany
As the world’s largest medical trade fair, MEDICA in Düsseldorf remains the top event for decision-makers from all over the world.
News & Events
Amoy Diagnostics exhibits in the18th World Conference on Lung Cancer(WCLC) in Yokohama, Japan
The 18th World Conference on Lung Cancer (WCLC) was held in Yokohama, Japan this week. It is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, organized by
News & Events
Detection sensitivity or therapeutic response prediction accuracy, which weighs more on NSCLC EGFR blood testing?
Recently an AURA 17 extension study was presented at the 2017 EMSO (European Society for Medical Oncology) Annual Congress in Madrid by experts on lung cancer from China. and the study evaluated the efficacy
News & Events
AmoyDx to develop CDx for CANbridge Glioblastoma Candidate
CANbridge Life Sciences will partner with Amoy Diagnostics Co., Ltd. (AmoyDx) to develop a companion diagnostic for its lead candidate, the glioblastoma multiforme (GBM) treatment CAN008, the companies said today, through a collaboration whose value was n
News & Events
AmoyDx in European Lung Cancer Conference (ELCC) 2017
The European Lung Cancer Conference (ELCC) is a collaborative effort of the most important multidisciplinary societies representing thoracic oncology specialists, all working towards a shared goal: to advance
News & Events
AmoyDx ROS1 Fusion Test Kit was Approved by Japanese Authority as Companion Diagnostics Kit for Pfizer's Crizotinib
February 3, 2017 – Amoy Diagnostics of Xiamen, China today announced that it has received regulatory approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for its ROS1 fusion PCR assay as a
News & Events
Super-ARMS® EGFR Mutation Detection Kit

Super-ARMS® EGFR Mutation Detection Kit

Currently there are several EGFR-TKIs approved for NSCLC (Non-small Cell Lung Cancer) targeted therapy including first-generation TKIs (gefitinib and erlotinib), second-generation TKI (afatinib) and third-generation TKI (osimertinib). To select right patients for these therapies, it is essential to detect EGFR mutation status before the treatment decision.

NSCLC tissue testing has been applied to EGFR mutation detection for years. However, up to 25% of patients with advanced or metastatic NSCLC do not have an available or sufficient tumor tissue sample for this method of testing. More and more dynamic monitoring demand for EGFR mutation status appears. When tissue sample is not a reliable or realistic option, the ctDNA (circulating tumor DNA) obtained from blood sample can be used for the assessment of EGFR mutation status.

Super-ARMS® EGFR kit is a highly sensitive, real-time PCR-based test which is designed to identify ctDNA EGFR mutation in plasma samples for patients with advanced or metastatic NSCLC. The kit adopts innovative Super-ARMS® technology which is upgraded from ADx-ARMS technology. Its optimized reaction system can rapidly and accurately detect low percentage of mutant ctDNA in a background of wild-type DNA.
 

Technological Principles:

The Super-ARMS® EGFR mutation kit enables detection of the following 42 EGFR mutations:

• Exon 18: G719C, G719A, G719S

• Exon 19: 29 deletions

• Exon 20: T790M, S768I, 6 insertions

• Exon 21: L858R, L861Q

PRODUCTS
MSDS-Super-ARMS KRAS&NRAS&BRAF-201804
DOWNLOAD
MSDS-Super-ARMS EGFR-201804
DOWNLOAD
MSDS-Super-ARMS EGFR T790M-201804
DOWNLOAD
Super-ARMS® EGFR C797S Mutation Detection Kit-B1.0-12T
DOWNLOAD
MSDS-Super-ARMS EGFR Color Compensation kit -201804
DOWNLOAD
Super-ARMS® KRASNRASBRAF Mutations Detection Kit-B2.2-24T
DOWNLOAD
Super-ARMS® EGFR T790M Mutation Detection Kit-B2.2-24T
DOWNLOAD
Super-ARMS® EGFR Mutation Detection Kit-B1.2-12T
DOWNLOAD
no more...
Visit AmoyDx at the 19th World Conference on Lung Cancer (WCLC) 2018 in Canada
Amoy Diagnostics will be exhibiting at 19th World Conference on Lung Cancer 2018 of IASLC in Toronto, Canada. Welcome to visit us at booth 206.
News & Events
Meet AmoyDx at ELCC 2018 in Switzerland for NSCLC Molecular Testing
Amoy Diagnostics will be exhibiting at the ELCC 2018 in Geneva, Switzerland. Welcome to visit us.  The exhibition details are below.
News & Events
China NMPA grants approval to AmoyDx Super-ARMS EGFR mutation test kit
(January 22, 2018, Xiamen China)  Amoy Diagnostics Co., Ltd. (AmoyDx, SZ:300685)  announced that NMPA(National Medical Products Administration)approved AmoyDx Super-ARMS® EGFR mutation test kit
News & Events
AmoyDx Distributors Annual Meeting (APAC-MEAF) 2017
AmoyDx Distributors Annual Meeting (APAC-MEAF) 2017 was held in Xiamen, China on December 4. Distributors from different countries gathered to get the recent update on precision oncology
News & Events
AmoyDx Distributors Annual Meeting (Europe) 2017
AmoyDx Distributors Annual Meeting (Europe) 2017 was held in Dusseldorf, Germany on November 15. Distributors from different European countries gathered to get the recent update on precision oncology
News & Events
Visit AmoyDx at MEDICA 2017, Germany
As the world’s largest medical trade fair, MEDICA in Düsseldorf remains the top event for decision-makers from all over the world.
News & Events
Amoy Diagnostics exhibits in the18th World Conference on Lung Cancer(WCLC) in Yokohama, Japan
The 18th World Conference on Lung Cancer (WCLC) was held in Yokohama, Japan this week. It is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, organized by
News & Events
Detection sensitivity or therapeutic response prediction accuracy, which weighs more on NSCLC EGFR blood testing?
Recently an AURA 17 extension study was presented at the 2017 EMSO (European Society for Medical Oncology) Annual Congress in Madrid by experts on lung cancer from China. and the study evaluated the efficacy
News & Events
AmoyDx to develop CDx for CANbridge Glioblastoma Candidate
CANbridge Life Sciences will partner with Amoy Diagnostics Co., Ltd. (AmoyDx) to develop a companion diagnostic for its lead candidate, the glioblastoma multiforme (GBM) treatment CAN008, the companies said today, through a collaboration whose value was n
News & Events
AmoyDx in European Lung Cancer Conference (ELCC) 2017
The European Lung Cancer Conference (ELCC) is a collaborative effort of the most important multidisciplinary societies representing thoracic oncology specialists, all working towards a shared goal: to advance
News & Events
AmoyDx ROS1 Fusion Test Kit was Approved by Japanese Authority as Companion Diagnostics Kit for Pfizer's Crizotinib
February 3, 2017 – Amoy Diagnostics of Xiamen, China today announced that it has received regulatory approval from Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for its ROS1 fusion PCR assay as a
News & Events
no more...
Super-ARMS® EGFR Mutation Detection Kit

Super-ARMS® EGFR Mutation Detection Kit

Currently there are several EGFR-TKIs approved for NSCLC (Non-small Cell Lung Cancer) targeted therapy including first-generation TKIs (gefitinib and erlotinib), second-generation TKI (afatinib) and third-generation TKI (osimertinib). To select right patients for these therapies, it is essential to detect EGFR mutation status before the treatment decision.

NSCLC tissue testing has been applied to EGFR mutation detection for years. However, up to 25% of patients with advanced or metastatic NSCLC do not have an available or sufficient tumor tissue sample for this method of testing. More and more dynamic monitoring demand for EGFR mutation status appears. When tissue sample is not a reliable or realistic option, the ctDNA (circulating tumor DNA) obtained from blood sample can be used for the assessment of EGFR mutation status.

Super-ARMS® EGFR kit is a highly sensitive, real-time PCR-based test which is designed to identify ctDNA EGFR mutation in plasma samples for patients with advanced or metastatic NSCLC. The kit adopts innovative Super-ARMS® technology which is upgraded from ADx-ARMS technology. Its optimized reaction system can rapidly and accurately detect low percentage of mutant ctDNA in a background of wild-type DNA.
 

Technological Principles:

The Super-ARMS® EGFR mutation kit enables detection of the following 42 EGFR mutations:

• Exon 18: G719C, G719A, G719S

• Exon 19: 29 deletions

• Exon 20: T790M, S768I, 6 insertions

• Exon 21: L858R, L861Q

PRODUCTS
no more...
Inquiry
* Required information
Manage your account info
Change your password